Home | Welcome to Contract Pharma   
Last Updated Wednesday, July 23 2014
Print

Financial Report: Baxter



Published April 17, 2014
Related Searches: Vaccine Development
Baxter

1Q Revenues: $4.0 billion (+15%)

1Q Earnings: $556 million (+1%)

Comments: BioScience revenues were $1.6 billion, up 5%, driven by growth of ADVATE and FEIBA, improved U.S. sales of plasma-based therapeutics including GAMMAGARD LIQUID, and milestone payments related to ongoing collaborations with governments on flu vaccine development. Medical Products sales increased 22% to $2.3 billion, augmented by the Gambro acquisition, which contributed $400 million. R&D expenses were $313 million up 27%.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On